JoVE Logo
Centro de Recursos para Docentes

Entrar

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

DOI :

10.3791/58270-v

December 4th, 2018

December 4th, 2018

7,038 Views

1Dept. of Hematology, Oncology and Immunology, University of Tübingen, 2Dept. of Endocrinology, Diabetology, Clinical Pathology and Metabolism, University of Tübingen

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. NFAT transcription factors are important regulators of development and activation in numerous cell types. Here, we present a protocol for the use of chromatin immunoprecipitation (ChIP) in human CLL cells to identify novel target genes of NFAT2.

Tags

Chromatin Immunoprecipitation Assay

-- Visualizações

Vídeos Relacionados

article

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

article

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

article

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

article

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

article

Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres

article

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

article

Assessment of the Metabolic Profile of Primary Leukemia Cells

article

In Vitro Assay to Study Tumor-macrophage Interaction

article

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

article

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

JoVE Logo

Privacidade

Termos de uso

Políticas

Pesquisa

Educação

SOBRE A JoVE

Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados